Business
Arius highlighted at AACR-NCI-EORTC 2007 International Cancer Conference
Arius highlighted at AACR-NCI-EORTC 2007 International Cancer Conference.
About this update from Affinity Metals Corp
[{"type":"text","content":"\n\n\n\nSelected for oral presentation and two media highlight spots at AACR\n\n\npress conference\n\n\nTORONTO, Oct. 16 /CNW/ - ARIUS Research Inc., (TSX: ARI), a biotechnology\ncompany discovering and developing the next wave of antibody therapeutics,\ntoday announced that it has been selected to deliver a proffered paper in an\noral presentation on one of the six abstracts it will present at the\nAACR-NCI-EORTC 2007 International Conference on Molecular Targets and Cancer\nTherapeutics, held on October 22nd-26th in San Francisco. The Company will\ndeliver presentations that will disclose new findings related to its CD44,\nTROP-2, CD59, CD9 and MCSP antibody programs. ARIUS scientists have also been\nselected to discuss two of the Company's abstracts at the AACR press\nconference.\n\n\n"The inclusion of six ARIUS abstracts, two media highlight spots and one\noral presentation in this year's AACR-NCI-EORTC conference is an important\naccomplishment for our Company, reflecting the high quality of our research\nand the scientific community's interest in our programs," said Dr. David\nYoung, President and CEO. "We are especially proud that our Trop-2 Signal\nTransduction Program abstract was one of only 12 selected from more than\n900 abstracts for presentation as a proffered paper. Being chosen for an oral\npresentation slot at this important conference is a highly-regarded\nachievement and will attract greater attention to our cancer drug portfolio."\n\n\nARIUS scientists Dr. Amandine Truong, Ph.D. and Dr. Baldwin Mak, Ph.D.\nwill discuss the Company's findings for the following two abstracts at the\nAACR press conference on Thursday, October 25th at 9:30 a.m. PT.\n\n\nPresentation PR12:\n\n\n"AR47A6.4.2, a functional naked monoclonal antibody targeting Trop-2,\ndemonstrates in vivo efficacy in human pancreatic, colon, breast and prostate\ncancer models." Proffered Paper Session 3, Thursday, October 25, 2007 from\n5:15 - 5:30 p.m. in the Third Floor Ballroom at Moscone Center.\n\n\nARIUS' abstract and accompanying oral presentation examine the mechanism\nof action of its Trop-2 targeting antibody. Trop-2 is a protein expressed on\nthe cell-surface and found in many cancer indications including pancreatic,\ncolon, breast and prostate cancer. The target is thought to be a key part of\nthe expansive MA...